Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

J Natl Cancer Inst. 2003 Aug 6;95(15):1174-5; author reply 1175. doi: 10.1093/jnci/djg020.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Neoplasms / complications*
  • Bone Neoplasms / prevention & control
  • Bone Neoplasms / secondary
  • Diphosphonates / therapeutic use*
  • Fractures, Spontaneous / etiology
  • Fractures, Spontaneous / prevention & control*
  • Humans
  • Imidazoles / therapeutic use*
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Treatment Outcome
  • Zoledronic Acid

Substances

  • Antineoplastic Agents
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid